Cover Image
市場調查報告書

Immune Targeting Systems (ITS) Ltd. - 產品平台分析

Immune Targeting Systems (ITS) Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 310064
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Immune Targeting Systems (ITS) Ltd. - 產品平台分析 Immune Targeting Systems (ITS) Ltd. - Product Pipeline Review - 2014
出版日期: 2014年07月31日 內容資訊: 英文 20 Pages
簡介

生命科學企業Immune Targeting Systems (ITS) Ltd.正在開發持續變異的病毒用合成疫苗。主力產品有震撼全球的A型流感用合成疫苗,以季節性及具有世界性流行可能性的各種流感細胞株為標的,目前進行到第?層臨床實驗。

本報告提供Immune Targeting Systems (ITS) Ltd.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Immune Targeting Systems (ITS) Ltd.的基本資料

Immune Targeting Systems (ITS) Ltd.概要

  • 主要資訊
  • 企業資料

Immune Targeting Systems (ITS) Ltd.:R&D概要

  • 主要的治療範圍

Immune Targeting Systems (ITS) Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Immune Targeting Systems (ITS) Ltd.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Immune Targeting Systems (ITS) Ltd.:藥物簡介

  • FP-01
  • Oncosyn
  • FP-02
  • 各給藥途徑
  • 各分子類型

Immune Targeting Systems (ITS) Ltd.:最近的開發平台趨勢

Immune Targeting Systems (ITS) Ltd.:總公司和子公司的所在地

附錄

圖表

目錄
Product Code: GMDHC05774CDB

Summary

Global Markets Direct's, 'Immune Targeting Systems (ITS) Ltd. - Product Pipeline Review - 2014', provides an overview of the Immune Targeting Systems (ITS) Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immune Targeting Systems (ITS) Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Immune Targeting Systems (ITS) Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Immune Targeting Systems (ITS) Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Immune Targeting Systems (ITS) Ltd.'s pipeline products

Reasons to buy

  • Evaluate Immune Targeting Systems (ITS) Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Immune Targeting Systems (ITS) Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Immune Targeting Systems (ITS) Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Immune Targeting Systems (ITS) Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immune Targeting Systems (ITS) Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Immune Targeting Systems (ITS) Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immune Targeting Systems (ITS) Ltd. Snapshot
    • Immune Targeting Systems (ITS) Ltd. Overview
    • Key Information
    • Key Facts
  • Immune Targeting Systems (ITS) Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Immune Targeting Systems (ITS) Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Immune Targeting Systems (ITS) Ltd. - Pipeline Products Glance
    • Immune Targeting Systems (ITS) Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Immune Targeting Systems (ITS) Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Immune Targeting Systems (ITS) Ltd. - Drug Profiles
    • FP-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncosyn
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FP-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immune Targeting Systems (ITS) Ltd. - Pipeline Products by Route of Administration
    • Immune Targeting Systems (ITS) Ltd. - Pipeline Products by Molecule Type
  • Immune Targeting Systems (ITS) Ltd. - Recent Pipeline Updates
  • Immune Targeting Systems (ITS) Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immune Targeting Systems (ITS) Ltd., Key Information
  • Immune Targeting Systems (ITS) Ltd., Key Facts
  • Immune Targeting Systems (ITS) Ltd. - Pipeline by Indication, 2014
  • Immune Targeting Systems (ITS) Ltd. - Pipeline by Stage of Development, 2014
  • Immune Targeting Systems (ITS) Ltd. - Monotherapy Products in Pipeline, 2014
  • Immune Targeting Systems (ITS) Ltd. - Phase II, 2014
  • Immune Targeting Systems (ITS) Ltd. - Preclinical, 2014
  • Immune Targeting Systems (ITS) Ltd. - Discovery, 2014
  • Immune Targeting Systems (ITS) Ltd. - Pipeline by Route of Administration, 2014
  • Immune Targeting Systems (ITS) Ltd. - Pipeline by Molecule Type, 2014
  • Immune Targeting Systems (ITS) Ltd. - Recent Pipeline Updates, 2014

List of Figures

  • Immune Targeting Systems (ITS) Ltd. - Pipeline by Top 10 Indication, 2014
  • Immune Targeting Systems (ITS) Ltd. - Pipeline by Stage of Development, 2014
  • Immune Targeting Systems (ITS) Ltd. - Monotherapy Products in Pipeline, 2014
  • Immune Targeting Systems (ITS) Ltd. - Pipeline by Top 10 Molecule Type, 2014
Back to Top